Optimi Health (OPTI) investor relations material

Company overview and business model

• Canadian GMP-compliant pharmaceutical manufacturer specializing in MDMA and psilocybin from botanical sources, licensed by Health Canada for controlled substances.

• Vertically integrated with two 10,000 sq ft production facilities in Princeton, BC, operating under a Drug Establishment Licence (DEL) and Dealer's Licence (DL).

• Products are available in Australia (prescription for TRD and PTSD), Canada (Special Access Program), and for clinical trials in Israel and the UK.

• Focus on sustainable, responsible production, advanced extraction technologies, and proprietary know-how rather than patents.

• Transitioned from nutraceuticals to pharmaceutical-grade manufacturing, winding down retail operations to focus on regulated drug products.

Financial performance and metrics

• For the nine months ended June 30, 2026: revenue C$239,700, net loss C$5,552,091; as of June 30, 2026, assets C$25.9M, liabilities C$8.2M, equity C$17.6M.

• For the year ended September 30, 2025: revenue C$426,301, net loss C$3,712,031; accumulated deficit C$31.4M as of June 30, 2026.

• Cash and cash equivalents as of June 30, 2026: C$13.1M; operating cash outflow for nine months ended June 30, 2026: C$3.8M.

• Company has a history of operating losses and relies on equity and debt financing for ongoing operations.

Use of proceeds and capital allocation

• May receive up to $100M in gross proceeds from Seven Knots under the Purchase Agreement; actual proceeds depend on shares sold and price.

• Proceeds intended for working capital, general corporate purposes, potential acquisitions, and debt repayment; no specific allocations or acquisition agreements in place.

• Pending use, proceeds may be invested in investment-grade securities or held as cash.